AlphaFold

Basecamp Research Launches BaseFold: A Breakthrough in 3D Protein Structure Prediction of Large, Complex Protein Structures

Retrieved on: 
Tuesday, March 12, 2024
Research, Genomics, Health, Algorithm, Database, Biotechnology, Drug discovery, Intelligence, AlphaFold, 3D, Acquisition, AI, Protein, Deep learning, Biodiversity, Drug development, Therapy, Data, BioRxiv, NVIDIA, Work, Medical device

LONDON, March 12, 2024 /PRNewswire/ -- Basecamp Research, a world leader in artificial intelligence (AI)-based design of proteins and other biological systems, today announced the launch of BaseFold, its new deep learning model that predicts 3D structures of large, complex proteins more accurately than other AI-powered tools, including the industry gold standard, AlphaFold2. These data were recently published in bioRxiv.

Key Points: 
  • BaseFold was created by augmenting the AlphaFold2 model, which predicts the 3D structure of a protein based on its amino acid sequence, with BaseGraph.
  • Furthermore, Basecamp Research will be working with NVIDIA to optimise and productionise BaseFold for NVIDIA BioNeMo , a generative AI platform for drug discovery.
  • The scientific benchmark for determining protein structure is still via slow and time-consuming experimental methods such as X-ray crystallography.
  • A wide array of structure prediction models have since followed AlphaFold2, most notably CollabFold, ESMFold, OpenFold and RoseTTAFold.

Basecamp Research Launches BaseFold: A Breakthrough in 3D Protein Structure Prediction of Large, Complex Protein Structures

Retrieved on: 
Tuesday, March 12, 2024
Research, Genomics, Health, Algorithm, Database, Biotechnology, Drug discovery, Intelligence, AlphaFold, 3D, Acquisition, AI, Protein, Deep learning, Biodiversity, Drug development, Therapy, Data, BioRxiv, NVIDIA, Work, Medical device

LONDON, March 12, 2024 /PRNewswire/ -- Basecamp Research, a world leader in artificial intelligence (AI)-based design of proteins and other biological systems, today announced the launch of BaseFold, its new deep learning model that predicts 3D structures of large, complex proteins more accurately than other AI-powered tools, including the industry gold standard, AlphaFold2. These data were recently published in bioRxiv.

Key Points: 
  • BaseFold was created by augmenting the AlphaFold2 model, which predicts the 3D structure of a protein based on its amino acid sequence, with BaseGraph.
  • Furthermore, Basecamp Research will be working with NVIDIA to optimise and productionise BaseFold for NVIDIA BioNeMo , a generative AI platform for drug discovery.
  • The scientific benchmark for determining protein structure is still via slow and time-consuming experimental methods such as X-ray crystallography.
  • A wide array of structure prediction models have since followed AlphaFold2, most notably CollabFold, ESMFold, OpenFold and RoseTTAFold.

ISOMORPHIC LABS ANNOUNCES STRATEGIC MULTI-TARGET RESEARCH COLLABORATION WITH LILLY

Retrieved on: 
Sunday, January 7, 2024
Lilly, Dicarboxylic acid, Protein, Partnership, Drug discovery, Drug design, Biology, Isomorphic Labs, Eli Lilly and Company, AlphaFold, Next Generation, Intelligence, Therapy

LONDON, Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with Eli Lilly and Company. This marks Isomorphic Labs' first pharmaceutical partnership.

Key Points: 
  • LONDON, Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with Eli Lilly and Company.
  • Under the terms of the agreement, Isomorphic Labs will partner with Lilly to discover small molecule therapeutics against multiple targets and will receive an upfront cash payment of $45 million.
  • Isomorphic Labs operates autonomously within Alphabet, with its own dedicated resources and exclusive focus on the application of AI to drug discovery.
  • Building on the success of AlphaFold and working in collaboration with Google DeepMind, Isomorphic Labs has made remarkable progress in developing the Next Generation of AlphaFold .

ISOMORPHIC LABS ANNOUNCES STRATEGIC MULTI-TARGET RESEARCH COLLABORATION WITH NOVARTIS

Retrieved on: 
Sunday, January 7, 2024
Dicarboxylic acid, Protein, Drug discovery, Research, Labs, Biology, Isomorphism, Biomedical Research, AI, Biomedicine, AlphaFold, Next Generation, Patient, Intelligence, Medicine, Therapy, Isomorphic Labs

LONDON, Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with Novartis to discover small molecule therapeutics against three undisclosed targets.

Key Points: 
  • "Isomorphic Labs and Novartis hold a shared purpose to reimagine medicine to improve and extend people's lives," said Demis Hassabis, CEO and founder of Isomorphic Labs.
  • Isomorphic Labs operates autonomously within Alphabet, with its own dedicated resources and exclusive focus on the application of AI to drug discovery.
  • Building on the success of AlphaFold and working in collaboration with GoogleDeepMind, Isomorphic Labs has made remarkable progress in developing the Next Generation of AlphaFold .
  • Under the terms of the agreement, Isomorphic Labs will receive an upfront payment of $37.5 million from Novartis, in addition to Novartis funding of select research costs.

ISOMORPHIC LABS ANNOUNCES STRATEGIC MULTI-TARGET RESEARCH COLLABORATION WITH LILLY

Retrieved on: 
Sunday, January 7, 2024
Lilly, Dicarboxylic acid, Protein, Partnership, Drug discovery, Drug design, Biology, Isomorphic Labs, Eli Lilly and Company, AlphaFold, Next Generation, Intelligence, Therapy

LONDON, Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with Eli Lilly and Company. This marks Isomorphic Labs' first pharmaceutical partnership.

Key Points: 
  • LONDON, Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with Eli Lilly and Company.
  • Under the terms of the agreement, Isomorphic Labs will partner with Lilly to discover small molecule therapeutics against multiple targets and will receive an upfront cash payment of $45 million.
  • Isomorphic Labs operates autonomously within Alphabet, with its own dedicated resources and exclusive focus on the application of AI to drug discovery.
  • Building on the success of AlphaFold and working in collaboration with Google DeepMind, Isomorphic Labs has made remarkable progress in developing the Next Generation of AlphaFold .

ISOMORPHIC LABS ANNOUNCES STRATEGIC MULTI-TARGET RESEARCH COLLABORATION WITH NOVARTIS

Retrieved on: 
Sunday, January 7, 2024
Dicarboxylic acid, Protein, Drug discovery, Research, Labs, Biology, Isomorphism, Biomedical Research, AI, Biomedicine, AlphaFold, Next Generation, Patient, Intelligence, Medicine, Therapy, Isomorphic Labs

LONDON, Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with Novartis to discover small molecule therapeutics against three undisclosed targets.

Key Points: 
  • "Isomorphic Labs and Novartis hold a shared purpose to reimagine medicine to improve and extend people's lives," said Demis Hassabis, CEO and founder of Isomorphic Labs.
  • Isomorphic Labs operates autonomously within Alphabet, with its own dedicated resources and exclusive focus on the application of AI to drug discovery.
  • Building on the success of AlphaFold and working in collaboration with GoogleDeepMind, Isomorphic Labs has made remarkable progress in developing the Next Generation of AlphaFold .
  • Under the terms of the agreement, Isomorphic Labs will receive an upfront payment of $37.5 million from Novartis, in addition to Novartis funding of select research costs.

AWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate Clinical Trial Development

Retrieved on: 
Wednesday, November 29, 2023
Data Management, Technology, Pharmaceutical, Education, Training, Professional Services, Genetics, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Data Analytics, Health, Research, MSD, Root cause analysis, NYSE, SAP, Patient, Ecosystem, Artificial intelligence, Vaccine, Amazon SageMaker, Machine learning, Automation, Therapy, AlphaFold, Drug discovery, HPC, AMZN, Health care, AI, AWS, MRK, Drug development, Animal Health, Pharmaceutical industry, Merck, Accenture

As part of this initiative, Merck selected AWS as its preferred cloud services provider and Accenture as its professional services partner to transition core applications like SAP, machine learning (ML), and data warehouses to AWS—enabling Merck to help accelerate scientific research and discovery.

Key Points: 
  • As part of this initiative, Merck selected AWS as its preferred cloud services provider and Accenture as its professional services partner to transition core applications like SAP, machine learning (ML), and data warehouses to AWS—enabling Merck to help accelerate scientific research and discovery.
  • Merck has been working with AWS and Accenture since 2021 to help transform its value chain and accelerate its cloud migrations efforts.
  • Working in collaboration with Accenture, Merck also selected AWS to strengthen its high-performance computing (HPC) capabilities to accelerate therapeutic discovery.
  • Merck also created an internal academy to upskill its employees on cloud technologies including AWS services and to advance the company’s technology transformation.

Exscientia Business Update for Third Quarter 2023

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Research, Drug design, GBP, NSCLC, IND, MALT1, ESMO, Ovarian cancer, International, GMT, EST, Congress, Head, European Society for Medical Oncology, G&A, PKC, Colorectal cancer, Acute leukemia, Acquisition, Federal Reserve Bank, BMS, Growth, CDK7, ID, Risk, Bristol Myers Squibb, Jaundice, Merck Group, Pancreatic cancer, AlphaFold, Sumitomo Pharma, Lung cancer, LSD1, USD, AI, Berlin, Patient, Toxicity, AML, Automation, Pharmaceutical industry, Medical imaging, Rare-earth element, Fine chemical, Cryptocurrency, Bank, Sanofi

Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the third quarter of 2023, are summarised below.

Key Points: 
  • Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the third quarter of 2023, are summarised below.
  • Exscientia will host a conference call Thursday, November 9 at 1:30 p.m. GMT / 8:30 a.m. EST.
  • A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website .
  • The increase in revenue quarter over quarter was primarily due to $8.38 million in revenue recognised from the projects that Exscientia and BMS mutually determined not to proceed with further development of under the BMS collaboration.

New MLPerf Training and HPC Benchmark Results Showcase 49X Performance Gains in 5 Years

Retrieved on: 
Wednesday, November 8, 2023
Data Management, Technology, Professional Services, Other Science, Other Technology, Research, Data Analytics, Software, Artificial Intelligence, Science, Hardware, Quanta, Cloud, 3D, Weather, Texas Advanced Computing Center, LLM, Azure, High-performance computing, HPC, AlphaFold, Synthetic media, Organization, Generative, CTuning foundation, Prisma Labs, Dell, Diffusion, Machine learning, Fujitsu, Columbia University, Stability, Stable Diffusion, X-Fusion, AI, Red Hat, Quanta Cloud Technology, Lawrence Berkeley National Laboratory, Protein, Asus, Midjourney, Deep learning processor, Risk management, Cryptocurrency, Medical imaging, Supermicro, NVIDIA, Lenovo

Today, MLCommons® announced new results from two industry-standard MLPerf™ benchmark suites:

Key Points: 
  • Today, MLCommons® announced new results from two industry-standard MLPerf™ benchmark suites:
    The MLPerf Training v3.1 suite, which measures the performance of training machine learning models.
  • The MLPerf HPC (High Performance Computing) v.3.0 benchmark suite, which is targeted at supercomputers and measures the performance of training machine learning models for scientific applications and data.
  • The MLPerf Training benchmark suite comprises full system tests that stress machine learning models, software, and hardware for a broad range of applications.
  • To view the results for MLPerf Training v3.1 and MLPerf HPC v3.0 and find additional information about the benchmarks, please visit the Training and HPC benchmark pages.

OpenFold Drug Discovery AI Research Consortium Announces Funding of Large-Scale Protein Data Collection at Prof. Gabriel Rocklin’s Laboratory at Northwestern University

Retrieved on: 
Monday, October 2, 2023
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Artificial Intelligence, Other Science, University, Research, Software, Education, Health Technology, Science, Data Management, Columbia University, Learning, Protein Data Bank, Nature, Therapy, Protein, Bayer, Deep learning, Protein folding, Multimedia, Algorithm, Research in Computational Molecular Biology, Drug discovery, Biology, Artificial intelligence, AI, Northwestern University, AlphaFold, Copper, Vaccine

OpenFold is a project of the Open Molecular Software Foundation (OMSF), a non-profit organization advancing molecular sciences by building communities for open-source research software development.

Key Points: 
  • OpenFold is a project of the Open Molecular Software Foundation (OMSF), a non-profit organization advancing molecular sciences by building communities for open-source research software development.
  • Prof. Rocklin’s lab is a pioneer in the creation of high-quality, large-scale, open protein data to improve AI models.
  • OpenFold and AlphaFold depend on the Protein Data Bank resource for learning to predict protein structures, but no similar resources currently exist for learning the principles of protein stability and function.
  • “Open data is a foundational resource powering the AI revolution in protein science, and we are completely aligned with OpenFold’s commitment to sharing and collaboration.”